Navigation Links
Progress Reported Against Gene Involved in Hepatitis C
Date:3/18/2009

Finding could lead to new treatments for the disease, researchers say,,,,

WEDNESDAY, March 18 (HealthDay News) -- Nearly 100 genes that support replication of the hepatitis C virus (HCV) in the human body have been identified by Massachusetts General Hospital researchers.

They also found that blocking several of the genes suppressed replication of the virus.

"We may be a few years away from developing therapies based on these findings, but this study is a proof of principle that targeting host factors is a viable therapeutic strategy," Dr. Andrew Tai, of the hospital's gastrointestinal unit and lead researcher on the study, said in a hospital news release.

Long-term HCV infection can lead to liver failure or liver cancer. Currently, a six- to 11-month regimen of peginterferon and the antiviral drug ribavirin is used to treat HCV, but the therapy can cause serious side effects and is ineffective in many people.

Tai and his colleagues examined whether using small interfering RNAs (siRNAs) to block each of the approximately 21,000 predicted messenger RNA transcripts in the human genome had any effect on HCV replication. The siRNA scan identified 96 genes that appear to play a role in HCV replication, and the researchers took a closer look at several of those genes.

One of the genes encodes for an enzyme called PI4KA, believed to play a role in the formation of membrane structures within the cell that may be the site of HCV replication. Another group of genes contributes to formation of the COPI coat that covers several types of cellular vesicles and plays a role in the replication of poliovirus, the researchers said.

They also zeroed in on the gene for a liver protein (hepcidin) that regulates iron absorption. People with chronic HCV infection experience elevated iron levels in the liver and blood.

Blocking each of these genes prevented HCV replication, as did drugs that inhibi
'/>"/>

Copyright©2009 ScoutNews,LLC.
All rights reserved  

Page: 1 2

Related medicine news :

1. New MRI finding sheds light on multiple sclerosis disease progressio
2. Brain Lesions Predict MS Progression
3. Pregnancy may slow -- not accelerate -- progression to AIDS
4. STAAR Surgical Reports Operational Progress
5. Progression of SIV infection in monkeys raises
6. Study makes progress in zoning in on biomarkers for better colon cancer treatment
7. Chemotherapy with gemcitabine delays progression of operable pancreatic cancer
8. Limiting refined carbohydrates may stall AMD progression
9. World Bank Group Report on Malaria in Africa Highlights Progress Towards Goal of Significantly Reducing Malaria Deaths
10. New Data Suggests Progression of Disability at Two Years Predicts Multiple Sclerosis (MS) Disability Progression at Eight Years
11. Study finds genetic influence on pace of HIV/AIDS progression
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Progress Reported Against Gene Involved in Hepatitis C
(Date:10/22/2014)... October 22, 2014 Although there are only 24 ... for many people who have trouble finding time within their busy ... exercise for long periods of time to get in shape. Here ... while on the go. , Change Up Your Commute , ... work to add some exercise into your daily routine. If you ...
(Date:10/22/2014)... Steven Reinberg HealthDay Reporter , ... add weight and length may be showing a genetic propensity ... adults, certain genes have been linked to increased body fat, ... fat and lean muscle, the researchers said. At 1 ... By ages 2 and 3, however, these genes were linked ...
(Date:10/22/2014)... HealthDay Reporter TUESDAY, Oct. 21, ... vitro fertilization (IVF) -- the incubation of embryos in a ... inside the vagina, new research suggests. Scientists from the ... INVOcell, might sharply cut costs for pricey IVF procedures among ... to those who don,t live near big-city assisted reproduction centers, ...
(Date:10/20/2014)... The newly updated Worldwide Medical Market ... of facts, figures and forecasts on the global medical ... forecast categories the Worldwide Medical Market Forecasts to ... views on the worldwide medical market to reveal key ... you data for 2010-2019, covering each country market individually, ...
(Date:10/20/2014)... ASCNYC (ascnyc.org) is a New ... Yorkers living with HIV/AIDS and other chronic conditions ... and self-sufficiency. Each year, ASCNYC spotlights selected “Positive ... their tireless efforts. , Savills Studley ... been selected as this year’s honoree for sharing ...
Breaking Medicine News(10 mins):Health News:HealthGuideMD Presents Ways to Improve Your Exercise and Fitness 2Health News:Tall, Heavy 1-Year-Olds May Be at Risk for Obesity Later, Study Finds 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 2Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 4Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 2Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 3
... 13 - Global innovation firm frog design today ... team with several new appointments. The new hires ... and building on its strong growth in multiple ... and brand strategy. Previously Creative Director for Nike,s ...
... 13 Genomic Health, Inc. (Nasdaq: GHDX ... Operating and Financial Officer, will present at the Eighth ... Tuesday, May 19, 2009 at 11:00 a.m. PT.To access ... visit the Investor Relations section of Genomic Health,s website ...
... 13 Celator Pharmaceuticals today announced that Scott Jackson, ... 2009 BIO International Convention in Atlanta. Mr. Jackson ... the company,s progress with two ongoing Phase 2 clinical ... (AML) patients and first-relapse AML patients. The presentation ...
... Fla., May 13 Ever since she was 6 years ... years of hard work and education she has her own ... their parents every day who want better health and more ... her new book, "Common Sense Pediatrics" ( published by ...
... Intelligent Charge Capture Emerges as Preferred Technology ... MedAptus(R), market leader for charge capture technologies, ... Physicians (UMP), a premier multi-specialty physician ... for charge capture automation.Founded in 1997 and ...
... Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL ) today announced ... officer, is scheduled to present a company overview at the ... Wednesday, May 20th at 2:00 p.m. PT.To access the live ... www.rigel.com . Please connect to Rigel,s website several minutes ...
Cached Medicine News:Health News:frog design Strengthens Creative Leadership With New Appointments 2Health News:Celator(R) Pharmaceuticals to Present at 2009 BIO International Convention 2Health News:'Common Sense Pediatrics': Combining Alternative and Traditional Medicine in Everyday Practice 2Health News:University of Minnesota Physicians Chooses MedAptus Following Comprehensive Vendor Review 2Health News:University of Minnesota Physicians Chooses MedAptus Following Comprehensive Vendor Review 3
(Date:10/22/2014)... 2014 Moms are ready to live the ... and their kids, according to the results of the ... Go Mobile for Moms, the latest installment in BabyCenter,s ... 1 pregnancy and parenting web and mobile destination worldwide, ... moms surveyed say they can,t think of a reason ...
(Date:10/22/2014)... , Oct. 22, 2014  Paper Pak ... has developed APLS ® Body Guard Bio, ... the spread of bacteria and virus while protecting ... Body Guard Bio features a rugged, external nylon ... that create a leak-proof inner chamber that contains ...
(Date:10/22/2014)... , Oct. 22, 2014 AVACEN Medical ... device received 510 (k) OTC clearance by the U.S. ... 100 to be marketed over the Internet for: ... muscle spasms; and minor strains and sprains . ... The AVACEN 100 (MSRP $2495) is a sophisticated medical ...
Breaking Medicine Technology:BabyCenter Finds Mom Ready to Live the "Measured Life" in its U.S. Mobile Mom 2014 Report: Health & Fitness Go Mobile for Moms 2BabyCenter Finds Mom Ready to Live the "Measured Life" in its U.S. Mobile Mom 2014 Report: Health & Fitness Go Mobile for Moms 3BabyCenter Finds Mom Ready to Live the "Measured Life" in its U.S. Mobile Mom 2014 Report: Health & Fitness Go Mobile for Moms 4New, State-Of-The-Art Body Bag Minimizes The Spread Of Bacteria And Virus 2AVACEN Medical Announces FDA Clearance of First Medical Device with Internal Game Mode 2
... PARSIPPANY, N.J. , Jan. 14 As ... market, the company has announced the addition of three Vice ... these positions bring a deep knowledge of the spine and ... distribution networks in their respective areas.   , Randy ...
... , HORSHAM, Pa. , ... 3 clinical study comparing the efficacy and safety of STELARA™ ... severe plaque psoriasis appear today in The New England ... clinical response with both doses of STELARA than with etanercept ...
Cached Medicine Technology:Custom Spine Announces the Expansion of its Sales Management Team 2STELARA(TM) Shows Greater Efficacy Than Etanercept for Treatment of Moderate to Severe Plaque Psoriasis: Phase 3 Comparator Study Published in The New England Journal of Medicine 2STELARA(TM) Shows Greater Efficacy Than Etanercept for Treatment of Moderate to Severe Plaque Psoriasis: Phase 3 Comparator Study Published in The New England Journal of Medicine 3STELARA(TM) Shows Greater Efficacy Than Etanercept for Treatment of Moderate to Severe Plaque Psoriasis: Phase 3 Comparator Study Published in The New England Journal of Medicine 4STELARA(TM) Shows Greater Efficacy Than Etanercept for Treatment of Moderate to Severe Plaque Psoriasis: Phase 3 Comparator Study Published in The New England Journal of Medicine 5STELARA(TM) Shows Greater Efficacy Than Etanercept for Treatment of Moderate to Severe Plaque Psoriasis: Phase 3 Comparator Study Published in The New England Journal of Medicine 6STELARA(TM) Shows Greater Efficacy Than Etanercept for Treatment of Moderate to Severe Plaque Psoriasis: Phase 3 Comparator Study Published in The New England Journal of Medicine 7STELARA(TM) Shows Greater Efficacy Than Etanercept for Treatment of Moderate to Severe Plaque Psoriasis: Phase 3 Comparator Study Published in The New England Journal of Medicine 8STELARA(TM) Shows Greater Efficacy Than Etanercept for Treatment of Moderate to Severe Plaque Psoriasis: Phase 3 Comparator Study Published in The New England Journal of Medicine 9
Lyphochek Assayed Chemistry Control requires no special diluent and has good reconstituted stability for enzymes and CO2. It is assayed for most major instruments and methodologies....
Lyphochek Benzo/TCA Control Set A is ideal for monitoring HPLC methods for identification and quantitation of benzodiazepines and tricyclic antidepressant drugs....
Lyphochek Benzo/TCA Control Set B is ideal for monitoring HPLC methods for identification and quantitation of benzodiazepines and antidepressant drugs....
Lyphochek Therapeutic Drug Monitoring Control (TDM) contains over 40 analytes with assayed values at three clinically significant levels....
Medicine Products: